Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13099
Title: A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Authors: Norman, Trevor R;Burrows, Graham D
Affiliation: Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Jan-1995
Citation: Drug Safety; 12(1): 46-54
Abstract: Moclobemide, a novel benzamide, is a reversible inhibitor of monoamine oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders. Comparative studies have shown that the drug is more effective than placebo and as effective as other antidepressants. In terms of efficacy, moclobemide offers no more benefits than do existing agents. On the other hand, moclobemide is better tolerated than tricyclic antidepressants and, unlike irreversible monoamine oxidase inhibitors, has a much lower propensity to cause a 'cheese reaction' (a potentially fatal syndrome caused by an interaction with tyramine-rich foods). These are significant clinical benefits, particularly in elderly patients. Furthermore, moclobemide lacks significant effects on psychomotor performance and cognitive function, has few clinically important drug interactions and is safe on overdose. The drug has a relatively short plasma elimination half-life, a property that allows a change to an alternative agent within 24 hours in cases of nonresponse. Since it is well tolerated, therapeutic dosages can often be achieved from the onset of treatment. These benefits need to be considered against the potential risks of moclobemide therapy. To date, the most significant hazards of therapy appear to arise from drug interactions with clomipramine or selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors, where the occurrence of the serotonin syndrome is potentially fatal. Similarly, in preclinical tests moclobemide has been shown to potentiate the effects of pethidine (meperidine) and dextropropoxyphene, so that combined use of moclobemide is a useful addition to the therapeutic agents used for depressive disorders.(ABSTRACT TRUNCATED AT 250 WORDS)
Internal ID Number: 7741983
URI: http://ahro.austin.org.au/austinjspui/handle/1/13099
URL: http://www.ncbi.nlm.nih.gov/pubmed/7741983
Type: Journal Article
Subjects: Antidepressive Agents.adverse effects.pharmacology.therapeutic use
Benzamides.adverse effects.pharmacology.therapeutic use
Blood Pressure.drug effects
Depressive Disorder.drug therapy
Drug Interactions
Drug Synergism
Humans
Moclobemide
Monoamine Oxidase Inhibitors.adverse effects.pharmacology.therapeutic use
Narcotics.adverse effects
Psychomotor Performance.drug effects
Risk Assessment
Tyramine.adverse effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.